Abstract
Overview
Introduction
With increasing regulatory clarity and the expiries of key patents covering
innovator biologics, the development of biosimilars for a range of recombinant
protein classes is becoming increasingly attractive. Although many companies
are targeting the market, 12 companies dominate. These include established
generics companies, leading biosimilars developers, plus emerging biosimilar
developers
Scope
- Overview of the biosimilars competitive landscape, examining how the key
players dominate the environment
- Update of in-depth profiles of the top-12 biosimilar developers
- Identification of licensing and collaboration trends shaping the
biosimilars environment
- Analysis of biosimilar development trends in terms of target protein
class, drug delivery and reformulation technology, and geographical launch
market
Report Highlights
Well-established generics companies such as Sandoz and Teva have led the drive
into the biosimilars market, by launching across a range of emerging and
Western markets in a small number of well-characterized and relatively simple
recombinant protein classes with significant market potential
Although established generics companies have so far dominated the biosimilars
landscape, emerging biosimilar developers have the greatest number of
disclosed pipeline biosimilar programs, which are set to broaden the range of
biosimilars being developed in terms of protein class, drug delivery and
formulation
There has been significant licensing and M&A deal activity among the top-12
biosimilars companies, enabling them to build a stronger product portfolio and
gain greater access to capabilities that are key to competing in this market,
such as drug delivery (primarily advanced injection technology) and drug
formulation (mainly pegylation) technologies
Reasons to Purchase
- Evaluate the competitive landscape of the top-12 biosimilar developers
- Identify the trends shaping biosimilar product development among the
top-12 biosimilar developers
- Understand the drivers for licensing and M&A deals being conducted by the
top-12 biosimilar developers
| 
View Cart
